View of Cost-Per-Responder Analysis of Delgocitinib Topical Cream Versus Dupilumab Subcutaneous Injection for Moderate to Severe Atopic Hand Eczema in the United States

Return to Article Details Cost-Per-Responder Analysis of Delgocitinib Topical Cream Versus Dupilumab Subcutaneous Injection for Moderate to Severe Atopic Hand Eczema in the United States Download Download PDF